跳至主要内容
临床试验/NL-OMON49077
NL-OMON49077已完成不适用

Development of a more sensitive method to predict breast cancer recurrence after 5-years of endocrine treatment making use of diagnostic leukapheresis to detect circulating tumor cells - Sibylla

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 87 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
87

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational invasive

入排标准

年龄范围
18 至 99(—)

入选标准

  • 2. Age >18 years
  • 3. Diagnosed with ER+ Her2-negative lymph node positive, primary breast cancer
  • 4. Received at least 4.5 - 5.5 years of adjuvant ET for breast cancer
  • including those who are <6 months after finishing endocrine therapy.
  • 5. No clinical signs of locoregional or distant recurrence.
  • 6. At least one adequate peripheral vein in both arms as access for
  • leukapheresis.
  • 7. Provide written informed consent

排除标准

  • 1. Prior non-breast malignancies <5 years of inclusion, except for basal or
  • squamous cell carcinoma of the skin
  • 2. Pre-existing lymphedema, quantified by specialist
  • 3. Known hypersensitivity to the used anticoagulant (ACD)
  • 4. Inadequate cardiac function or severe cardiovascular comorbidity (heart
  • failure NYHA class III/IV)
  • 5. Coagulation disorders as defined by one of the following:
  • NOTE: the use of all types of anticoagulant therapy is permitted
  • o Coagulation disorder in medical history
  • o Platelet count < 40 x 10^9/L;
  • Patients not on anticoagulant therapy which affects PT or APTT if:
  • o PT > 1.5 x ULN or PT-INR > 1.5 x ULN
  • o APTT > 1.5 x ULN
  • Patients who take anticoagulant therapy which affects PT or APTT if:
  • o PT or APTT > 1.5 x the upper limit of the desired therapeutic window
  • o Total bilirubin > 2.5 x ULN
  • 6. BMI >= 35 kg/m2

研究者

相似试验